We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Arcutis Biotherapeutics has enrolled the first patient ...
Odell Beckham Jr. first noticed flakes throughout his iconic beard and hairline in his 20s; today, for the first time he is sharing his experience with ZORYVE® (roflumilast) topical foam, 0.3%, to ...
Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S. Survey found that, among adults with seborrheic dermatitis who use treatments, only ...
WESTLAKE VILLAGE, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Please provide your email address to receive an email when new articles are posted on . Arcutis Biotherapeutics announced the results of a nationwide survey that revealed a lack of diagnosis ...
This article was reviewed by Knox Beasley, MD. Flakes on your scalp making you feel self-conscious? Let’s talk about seborrheic dermatitis vs dandruff. Whether your scalp feels like a snowglobe thanks ...
NEW YORK CITY -- A topical phosphodiesterase-4 (PDE4) inhibitor produced rapid improvement in seborrheic dermatitis, particularly scalp lesions, a randomized clinical trial showed. Two-thirds of ...
NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foam If approved, roflumilast foam would be the first topical drug for seborrheic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results